Amphastar Pharmaceuticals, Inc. (AMPH)
| Market Cap | 2.96B |
| Revenue (ttm) | 601.31M |
| Net Income (ttm) | 135.29M |
| Shares Out | 47.91M |
| EPS (ttm) | 2.55 |
| PE Ratio | 24.25 |
| Forward PE | 18.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 448,882 |
| Open | 62.20 |
| Previous Close | 62.17 |
| Day's Range | 60.85 - 62.87 |
| 52-Week Range | 27.58 - 67.66 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 59.00 (-4.61%) |
| Earnings Date | Feb 27, 2024 |
About AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep... [Read more]
Full Company ProfileFinancial Performance
In 2022, AMPH's revenue was $498.99 million, an increase of 13.98% compared to the previous year's $437.77 million. Earnings were $91.39 million, an increase of 47.12%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is $59.0, which is a decrease of -4.61% from the latest price.
News
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 20, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will p...
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi EVP of Corp. Administration, will parti...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" o...
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2023 ended September 30, 2...
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 13, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced the pricing of $300.0 million aggregate principal amount of 2.00% c...
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 11, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced that it intends to offer, subject to market conditions and other fa...
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operati...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
Reports Net Revenues of $145.7 Million for the Three Months Ended June 30, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "...
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 2, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2023 ended June 30, 2023, a...
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 30, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today announced that it has completed the previously announced acquisit...
Promising Small Biotech Amphastar Sees Actionable Pullback
Amphastar Pharmaceuticals Inc. NASDAQ: AMPH, a small cap that's one of the leading performers within the biotech space, is forming an orderly pullback and is currently actionable as it holds above its...
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner SVP of Corp. Communication, will participate in ...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Co...
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 3, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2023 ended March 31, 2023, afte...
Eli Lilly to sell hypoglycemia treatment for up to $1.1 billion in cash and milestone payments to Amphastar
Shares of Eli Lilly & Co. LLY gained 0.5% in premarket trading Monday, after the drugmaker announced an agreement to sell its hypoglycemia treatment for people with diabetes Baqsimi to Amphastar Pharm...
Lilly to Divest BAQSIMI to Amphastar
Lilly focused on delivering the company's unprecedented pipeline of next-generation medicines to help patients Amphastar is the ideal company to continue Lilly's mission to help more people benefit fr...
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 24, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will provide a Business update and hold a Conference call today, Monday, A...
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 12, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Jacob Liawatidewi, EVP of Corporate Administration, Tony Marrs...
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced that the U.S. Food and Drug Administration ("FDA") has grante...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022
Reports Net Revenues of $135.0 Million for the Three Months Ended December 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" o...
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / February 22, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2022 ended December 31, ...
Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Cl...
Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, Executive V.P. of Corporate Administr...
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 2...
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sale...